A Study of CS1002 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate
the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.